LBN 0.006% (n=82) | LBN 0.012% (n=85) | LBN 0.024% (n=83) | LBN 0.040% (n=81) | Latanoprost 0.005% (n=82) | Total (N=413) | p Value | |
---|---|---|---|---|---|---|---|
Age (years) | |||||||
Mean (SD) | 60.9 (11.39) | 61.6 (9.58) | 60.8 (11.47) | 60.3 (12.89) | 61.2 (11.92) | 61.0 (11.44) | 0.972† |
Median | 62.0 | 62.0 | 62.0 | 61.0 | 62.0 | 62.0 | |
Range | 24–85 | 31–84 | 38–81 | 30–85 | 29–89 | 24–89 | |
Gender, N (%) | |||||||
Male | 26 (31.7) | 39 (45.9) | 26 (31.3) | 38 (46.9) | 29 (35.4) | 158 (38.3) | 0.640‡ |
Female | 56 (68.3) | 46 (54.1) | 57 (68.7) | 43 (53.1) | 53 (64.6) | 255 (61.7) | |
Race, N (%) | |||||||
White | 61 (74.4) | 61 (71.8) | 62 (74.7) | 56 (69.1) | 66 (80.5) | 306 (74.1) | 0.485‡ |
Black or African American | 21 (25.6) | 23 (27.1) | 21 (25.3) | 23 (28.4) | 16 (19.5) | 104 (25.2) | |
American Indian or Alaskan Native | 0 | 1 (1.2) | 0 | 0 | 0 | 1 (1.2) | |
Asian | 0 | 0 | 0 | 1 (1.2) | 0 | 1 (1.2) | |
Other | 0 | 0 | 0 | 1 (1.2) | 0 | 1 (1.2) | |
Ethnicity, N (%) | |||||||
Hispanic or Latino | 5 (6.1) | 2 (2.4) | 8 (9.6) | 6 (7.4) | 11 (13.4) | 32 (7.7) | |
Non-Hispanic and non-Latino | 77 (93.9) | 83 (97.6) | 75 (90.4) | 75 (92.6) | 71 (86.6) | 381 (92.3) | |
Treatment-naive subject, N (%) | |||||||
Yes | 35 (42.7) | 39 (45.9) | 36 (43.4) | 35 (43.2) | 35 (42.7) | 180 (43.6) | 0.874‡ |
No | 47 (57.3) | 46 (54.1) | 47 (56.6) | 46 (56.8) | 47 (57.3) | 233 (56.4) | |
Previous IOP-lowering medication, N (%)* | |||||||
Prostaglandin analogue | 35 (74.5) | 38 (82.6) | 38 (80.9) | 35 (76.1) | 36 (76.6) | 182 (78.1) | |
β-Blocker | 13 (27.7) | 17 (37.0) | 17 (36.2) | 15 (32.6) | 19 (40.4) | 81 (34.8) | |
Carbonic anhydrase inhibitor | 10 (21.3) | 10 (21.8) | 6 (12.8) | 10 (21.7) | 7 (14.9) | 43 (18.5) | |
Sympathomimetics | 5 (10.6) | 2 (4.3) | 3 (6.4) | 0 | 3 (6.4) | 13 (5.6) | |
Baseline (Visit 3, Day 1) IOP* | |||||||
Mean (SD) | 26.12 (1.82) | 26.25 (1.88) | 26.01 (1.67) | 26.04 (1.51) | 26.15 (1.79) | 0.909† | |
Median | 25.67 | 25.67 | 25.67 | 25.83 | 25.67 | ||
Range | 23.83–32.00 | 22.67–31.83 | 23.17–30.67 | 24.00–30.83 | 23.50–31.17 |
Specific drugs within the previous IOP-lowering medications categories were as follows: (1) prostaglandin analogues: latanoprost, bimatoprost and travaprost; (2) β-blockers: timolol and carteolol; (3) carbonic anhydrase inhibitors: brinzolamide and dorzolamide; and (4) sympathomimetics: brimonidine. In all, 46 eyes were being treated with combination products: dorzolamide–timolol, brimonidine–timolol, latanoprost–timolol, bimatoprost–timolol, travaprost–timolol and brinzolamide–timolol.
*Study eye.
†ANOVA model with treatment effect.
‡χ2 Test comparing number of subjects among all treatment groups.
IOP, intraocular pressure; LBN, latanoprostene bunod.